Note 2 - Investments in Affiliates	9 Months Ended
Jan. 29, 2022
Notes to Financial Statements
Investment [Text Block]	Note 2. Investments in Affiliates The aggregate amount of our investments in affiliates accounted for under the equity method was $17,921 and $19,887 as of January 29, 2022 and May 1, 2021, respectively. Our proportional share of the respective affiliates' earnings or losses is included in the "Other (expense) income, net" line item in our condensed consolidated statements of operations. For the three and nine months ended January 29, 2022, our share of the losses of our affiliates was $401 and $1,966 as compared to $595 and $1,740 for the three and nine months ended January 30, 2021. We purchased services for research and development activities from our equity method investees. The total of these related party transactions was $1,520 for the nine months ended January 29, 2022, which is included in the "Product design and development" line item in our condensed consolidated statement of operations, and $117 of this remains unpaid and is included in the "Accounts payable " line item in our condensed consolidated balance sheet. We have loaned equity investees $6,335, which is evidenced by convertible notes (“Notes”) and included in the “Long-term receivables, less current maturities" line item in our condensed consolidated balance sheet.

Note 2 - Investments in Affiliates

9 Months Ended

Jan. 29, 2022

Note 2. Investments in Affiliates

The aggregate amount of our investments in affiliates accounted for under the equity method was $17,921 and $19,887 as of January 29, 2022 and May 1, 2021, respectively. Our proportional share of the respective affiliates' earnings or losses is included in the "Other (expense) income, net" line item in our condensed consolidated statements of operations. For the three and nine months ended January 29, 2022, our share of the losses of our affiliates was $401 and $1,966 as compared to $595 and $1,740 for the three and nine months ended January 30, 2021. We purchased services for research and development activities from our equity method investees. The total of these related party transactions was $1,520 for the nine months ended January 29, 2022, which is included in the "Product design and development" line item in our condensed consolidated statement of operations, and $117 of this remains unpaid and is included in the "Accounts payable " line item in our condensed consolidated balance sheet. We have loaned equity investees $6,335, which is evidenced by convertible notes (“Notes”) and included in the “Long-term receivables, less current maturities" line item in our condensed consolidated balance sheet.